Van Nguyen

Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma

Jeffrey S. Morris, Manal M. Hassan, James C Yao, 2016, OncoTargets and therapy.

Second-line systemic treatment for advanced cholangiocarcinoma.

M. Javle, R. Shroff, W. Qiao, 2014, Journal of gastrointestinal oncology.

Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature

G. Mills, B. Litzenburger, K. Shaw, 2017, Oncotarget.

Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma

Manal M. Hassan, M. Wallace, R. Murthy, 2016, Journal of hepatocellular carcinoma.

Phase ii trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma

Manal M. Hassan, R. Wolff, Lianchun Xiao, 2016 .

Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma

R. Murthy, A. Kaseb, K. Raghav, 2016, Journal of hepatocellular carcinoma.